E. Eigendorff

1.6k total citations · 1 hit paper
11 papers, 704 citations indexed

About

E. Eigendorff is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, E. Eigendorff has authored 11 papers receiving a total of 704 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 4 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in E. Eigendorff's work include Lung Cancer Diagnosis and Treatment (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Hormonal Regulation and Hypertension (4 papers). E. Eigendorff is often cited by papers focused on Lung Cancer Diagnosis and Treatment (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Hormonal Regulation and Hypertension (4 papers). E. Eigendorff collaborates with scholars based in Germany, United States and Japan. E. Eigendorff's co-authors include Heather A. Wakelee, Moïshe Liberman, Ayman Samkari, Olivier Bylicki, Terufumi Kato, Gastón Lucas Martinengo, Christophe Dooms, Jamie E. Chaft, Delvys Rodríguez‐Abreu and Margarita Majem and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

E. Eigendorff

11 papers receiving 697 citations

Hit Papers

Perioperative Pembrolizumab for Early-Stage Non–Small-Cel... 2023 2026 2024 2025 2023 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
    2023 460 citations Heather A. Wakelee, Moïshe Liberman et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Eigendorff Germany 7 466 379 107 92 64 11 704
Bruce Keith United States 10 262 0.6× 243 0.6× 47 0.4× 40 0.4× 86 1.3× 15 504
Jung Wook Park United States 11 284 0.6× 246 0.6× 17 0.2× 166 1.8× 31 0.5× 22 662
Fatih Köse Türkiye 13 161 0.3× 148 0.4× 27 0.3× 143 1.6× 38 0.6× 65 520
Nathan D. Seligson United States 13 165 0.4× 213 0.6× 56 0.5× 27 0.3× 26 0.4× 38 532
Rakesh Chopra India 8 164 0.4× 224 0.6× 18 0.2× 133 1.4× 37 0.6× 14 558
H. Ballentine Carter United States 9 268 0.6× 173 0.5× 133 1.2× 90 1.0× 18 0.3× 14 544
Yukihiko Ohishi Japan 11 180 0.4× 72 0.2× 95 0.9× 158 1.7× 25 0.4× 51 448
Antonio Pazzola Italy 15 478 1.0× 398 1.1× 33 0.3× 57 0.6× 14 0.2× 43 767
Hirotaka Asakura Japan 13 282 0.6× 95 0.3× 31 0.3× 130 1.4× 21 0.3× 48 558
A. Celma Spain 13 530 1.1× 98 0.3× 106 1.0× 64 0.7× 60 0.9× 97 727

Countries citing papers authored by E. Eigendorff

Since Specialization
Citations

This map shows the geographic impact of E. Eigendorff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Eigendorff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Eigendorff more than expected).

Fields of papers citing papers by E. Eigendorff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Eigendorff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Eigendorff. The network helps show where E. Eigendorff may publish in the future.

Co-authorship network of co-authors of E. Eigendorff

This figure shows the co-authorship network connecting the top 25 collaborators of E. Eigendorff. A scholar is included among the top collaborators of E. Eigendorff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Eigendorff. E. Eigendorff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Garassino, Marina Chiara, Heather A. Wakelee, Jonathan Spicer, et al.. (2024). Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8012–8012. 2 indexed citations
2.
Jones, David R., Moïshe Liberman, Terufumi Kato, et al.. (2024). OA01.03 Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC. Journal of Thoracic Oncology. 19(10). S8–S8. 5 indexed citations
3.
Wakelee, Heather A., Moïshe Liberman, Terufumi Kato, et al.. (2023). KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.. Journal of Clinical Oncology. 41(17_suppl). LBA100–LBA100. 11 indexed citations
4.
Gao, Shugeng, Moïshe Liberman, Terufumi Kato, et al.. (2023). LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). Annals of Oncology. 34. S1297–S1298. 51 indexed citations
5.
Wakelee, Heather A., Moïshe Liberman, Terufumi Kato, et al.. (2023). Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer. New England Journal of Medicine. 389(6). 491–503. 460 indexed citations breakdown →
6.
Tsuboi, Masahiro, Alexander Luft, Takeshi Kato, et al.. (2020). 1235TiP Perioperative pembrolizumab + platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: The phase III KEYNOTE-671 study. Annals of Oncology. 31. S801–S802. 18 indexed citations
7.
8.
Quinkler, Marcus, Knut Mai, M. Schöneshöfer, et al.. (2010). In Vivo Activity of 11β-Hydroxysteroid Dehydrogenase Type 1 in Man: Effects of Prednisolone and Chenodesoxycholic Acid. Hormone and Metabolic Research. 43(1). 66–71. 4 indexed citations
9.
10.
Quinkler, Marcus, Hanno Troeger, E. Eigendorff, et al.. (2003). Enhanced 11beta-hydroxysteroid dehydrogenase type 1 activity in stress adaptation in the guinea pig. Journal of Endocrinology. 176(2). 185–192. 8 indexed citations
11.
Diederich, Sven, E. Eigendorff, Marcus Quinkler, et al.. (2002). 11β-Hydroxysteroid Dehydrogenase Types 1 and 2: An Important Pharmacokinetic Determinant for the Activity of Synthetic Mineralo- and Glucocorticoids. The Journal of Clinical Endocrinology & Metabolism. 87(12). 5695–5701. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bruce Keith Breakdown of academic impact, for papers by Jung Wook Park Breakdown of academic impact, for papers by Fatih Köse Breakdown of academic impact, for papers by Nathan D. Seligson Breakdown of academic impact, for papers by Rakesh Chopra Breakdown of academic impact, for papers by H. Ballentine Carter Breakdown of academic impact, for papers by Yukihiko Ohishi Breakdown of academic impact, for papers by Antonio Pazzola Breakdown of academic impact, for papers by Hirotaka Asakura Breakdown of academic impact, for papers by A. Celma
Rankless by CCL
2026